Another interesting paper.
I have long believed that metabolomics might hold a key, or even a bunch of keys, to the impact of thyroid disorders. We know very well that some things are associated with high or low thyroid hormone levels but have little beyond that association.
Metabolomics might provide the finger to point at specific pathways and start to explain the actual routes of causation.
Over that, they might highlight issues which really do need to be looked it in those who have thyroid disorders.
For example:
notable changes were observed in … primary bile acid biosynthesis
And it has long appeared that bile issues are over-represented in those with thyroid issues. But pretty much everyone totally ignores that! At least a solid unwavering finger might result in people looking where it was pointing!
It is not an easy read. These things are almost never written with non-experts in mind. (Unfortunately, that includes most endocrinologists who are obviously rarely, if ever, metabolomics experts.). I’ve certainly found it tough getting through it. Nevertheless, it might well be worth a scan read - for as long as your eyes don’t glaze over.
Serum metabolomic analysis in patients with Hashimoto’s thyroiditis positive for TgAb or TPOAb: a preliminary study
Tao Luo, Xinyu Zhao, Xiao Jiang, Pengqian Li, Xiaotong Gu, Xingjie Xie & Haixia Liu
Scientific Reports volume 15, Article number: 9945 (2025)
Abstract
Hashimoto’s thyroiditis (HT) is a prevalent autoimmune disorder, yet the metabolic abnormalities associated with HT and their relationship to antibody positivity remain poorly understood. This study aimed to characterize the distinct metabolic profiles associated with thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) positivity in female patients with HT. Serum metabolomic analysis was performed on 14 TPOAb-positive patients, 4 TgAb-positive patients, and 14 sex-matched healthy controls, evaluating a total of 225 metabolites. Partial least squares discriminant analysis (PLS-DA) revealed significant metabolic differences among the groups, identifying 36 key metabolites. Of these, 13 metabolites showed significant differences between the TPOAb-positive group and healthy controls, while 23 metabolites exhibited marked differences between the TgAb-positive group and controls. Further correlation analysis revealed a moderate positive association between TgAb and phenylacetyl-L-glutamine, while TPOAb was strongly correlated with LPC 16:0 sn-1. Additionally, metabolic pathway analysis showed significant activation of glycine, serine, and threonine metabolism in the TPOAb-positive group, whereas the TgAb-positive group exhibited enhanced activity in galactose metabolism. These findings suggest that TPOAb and TgAb positivity are associated with distinct metabolic profiles, reflecting their differential roles in metabolic pathways linked to Hashimoto’s thyroiditis. This study provides valuable exploratory evidence of metabolic abnormalities in HT under different antibody-positive states, laying the foundation for future large-scale investigations to elucidate the underlying mechanisms.
Open access